STOCK TITAN

Helus Pharma HLP003 posts positive Phase 3 results

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Helus Pharma Inc. reported positive topline results from APPROACH, a Phase 3 study of HLP003 as adjunctive treatment for adults with major depressive disorder. At the six-week primary endpoint, the placebo-adjusted least-squares mean difference on the Montgomery-Asberg Depression Rating Scale (MADRS) was -7.6 points (p<0.0001); at the Week 12 key secondary endpoint, it was -7.0 points (p<0.0001). The Day 2 placebo-adjusted difference was -5.0 points (p=0.0013).

Response rates were 50.0% for HLP003 and 23.6% for placebo on Day 2, and 56.3% and 28.2%, respectively, at Week 6. The company said HLP003 was generally well tolerated; three treatment-related serious adverse events occurred, and no new safety signals were identified. APPROACH included 222 participants. The second pivotal study, EMBRACE, is ongoing, with topline results expected in 4Q 2027.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Major pointAPPROACH primary endpoint: -7.6-point placebo-adjusted MADRS difference at Week 6 (p<0.0001).

Negative

  • Minor pointThree treatment-related serious adverse events were reported in APPROACH.

Filing Explained

At the key secondary 12-week endpoint, HLP003 had a -7.0-point placebo-adjusted MADRS difference (p<0.0001), adding a reported durability result. The drug remains in Phase 3 development; regulatory approval and commercialization are prospective, not completed.

Placebo-adjusted MADRS difference, Week 6 -7.6 points APPROACH primary endpoint; p<0.0001
Placebo-adjusted MADRS difference, Week 12 -7.0 points APPROACH key secondary endpoint; p<0.0001
Placebo-adjusted MADRS difference, Day 2 -5.0 points APPROACH; p=0.0013
Response rate, Day 2 50.0% (HLP003); 23.6% (placebo) APPROACH
Response rate, Week 6 56.3% (HLP003); 28.2% (placebo) APPROACH
Participants 222 participants APPROACH intent-to-treat population
Treatment-related serious adverse events 3 events APPROACH
Montgomery-Asberg Depression Rating Scale medical
"on the Montgomery-Asberg Depression Rating Scale"
least squares mean technical
"least squares (“LS”) mean reduction"
Least squares mean is an average computed from a statistical model that adjusts for other influencing factors so groups can be compared fairly; think of it like comparing athletes’ times after accounting for different wind conditions. It matters to investors because regulators, clinical trial reports, and financial analyses often use these adjusted averages to present treatment effects or performance, and those numbers can materially affect perceived efficacy, approval chances, market expectations and valuation.
intent-to-treat population medical
"intent-to-treat population consisted of 222 participants"
The intent-to-treat population is the set of all participants who were assigned to a treatment group when a clinical trial began, counted in the final analysis regardless of whether they completed the treatment or followed the protocol. For investors, this matters because results reported on this basis tend to show how a therapy performs in real-world use—providing a conservative, less biased measure of effectiveness that regulators and markets rely on when assessing risk and potential value. Think of it like grading a cooking class by everyone who signed up, not just those who finished the recipe.
adjunctive treatment medical
"as an adjunctive treatment for adults with MDD"
An adjunctive treatment is a therapy given in addition to a primary treatment to improve overall effectiveness or manage side effects—think of it as a booster or supportive sidekick to the main medicine. For investors, adjunctive therapies matter because they can expand a product’s market use, create additional revenue streams, affect regulatory pathways and clinical trial design, and influence competitive positioning and pricing in a therapeutic area.
serious adverse events medical
"three HLP003 treatment-related serious adverse events"
Serious adverse events are significant problems or negative outcomes that occur during a medical treatment or clinical trial, such as severe side effects, hospitalizations, or life-threatening conditions. They matter to investors because such events can impact a company's reputation, lead to regulatory scrutiny, or delay the development of new products, ultimately affecting the company’s financial performance.
Breakthrough Therapy Designation regulatory
"has received Breakthrough Therapy Designation"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Helus Pharma expect results from the EMBRACE trial?

Helus Pharma expects to report topline results from EMBRACE in 4Q 2027. EMBRACE is the second pivotal study in the PARADIGM Phase 3 program and is ongoing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November, 2026.

 

Commission File Number: 001-40673


Helus Pharma Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9  

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

 

INCORPORATION BY REFERENCE

 

Exhibit 99.1 of this Form 6-K of Helus Pharma Inc. (the “Company”) other than the fifth and eighth paragraphs therein is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-292294) and the Registration Statement on Form S-8 (File No. 333-298692) of the Company, each as amended or supplemented.

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    HELUS PHARMA INC.
    (Registrant)
       
Date: November 16, 2026 By: /s/ Greg Cavers
    Name: Greg Cavers
    Title: Chief Financial Officer

 

 

 

EXHIBIT INDEX

 

99.1 News Release dated November 16, 2026

 

 

 

 

 

 

 

Exhibit 99.1

 

 

 

 

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder

 

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points

 

-7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001)

 

Durable effect maintained through Week 12 (key secondary endpoint) with a -7.0 point placebo-adjusted change from baseline on the MADRS (p< 0.0001)

 

Robust and statistically significant response and remission rates starting as early as Day 2 and maintained at all time points

 

HLP003 was generally well-tolerated

 

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

 

Company to host webcast at 8:00 AM ET today

 

NEW YORK and TORONTO, Nov. 16, 2026 — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma” or the “Company”), a  clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions through the development and commercialization of novel serotonergic agonists (“NSAs”), today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder (“MDD”).

 

HLP003 achieved statistically significant and clinically meaningful results in the primary, key secondary and other secondary endpoints starting as early as Day 2 and these were maintained at all time points.

 

At the primary endpoint of 6 weeks, the least squares (“LS”) mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo (LS mean difference = -7.6 points, p<0.0001, effect size=0.653).

 

 

 

The rapid onset of action with HLP003 was demonstrated with statistically significant LS mean MADRS reductions as early as Day 2 of 16.1 points versus 11.0 points for placebo (LS mean difference = -5.0 points, p=0.0013, effect size=0.438). This effect was durable with an LS mean reduction from baseline in the MADRS total score for HLP003 of 16.9 points versus 9.9 points for placebo (LS mean difference = -7.0 points, p<0.0001, effect size=0.581) at the key secondary endpoint of 12 weeks.

 

“The large unmet need for patients with major depressive disorder who continue to experience persistent symptoms underscores the importance of new rapid-acting and well-tolerated adjunctive treatment options,” said Michael Halstead, Chief Executive Officer of Helus Pharma. “We believe these data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients and strengthen our momentum as we continue to progress HLP003 toward regulatory approval and potential commercialization.”

 

Other Efficacy Results

 

HLP003 demonstrated statistically significant and clinically meaningful improvements in response and remission rates as an adjunctive therapy, starting as early as Day 2 and maintained at all time points:

 

 

HLP003

(N=112)

Placebo (N=110) p-value
Response rate (50% reduction from baseline)
at Day 2 50.0% 23.6% 0.0002
at Week 6 56.3% 28.2% <0.0001
at Week 12 45.5% 19.1% <0.0001
Remission rate (MADRS total score of ≤10)
at Day 2 39.3% 15.5% 0.0002
 at Week 6 50.9% 18.2% <0.0001
at Week 12 40.2% 15.5% <0.0001

 

Additionally, HLP003 demonstrated statistically significant improvements on the Clinical Global Impression Scale compared with placebo starting as early as Day 2 and maintained at all time points.

 

“The results from the APPROACH study set a new benchmark for what may be achievable with adjunctive treatment in major depressive disorder,” said Roger S. McIntyre, M.D., FRCPC, Professor of Psychiatry and Pharmacology, University of Toronto. “The magnitude of benefit

 

 

 

observed in this study is highly compelling and has the potential to redefine expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant.”

 

Approximately two-thirds of patients with depression do not achieve remission with first-line antidepressant treatment.1 For patients who experience an inadequate response, adjunctive therapy is a commonly used treatment strategy. By adding a therapy to an existing antidepressant regimen, clinicians may be able to enhance treatment response while avoiding the need for antidepressant discontinuation, medication washout periods, or the potential withdrawal symptoms associated with switching treatments.

 

Safety and Tolerability

 

HLP003 was generally well tolerated in the APPROACH study. Most adverse events were mild to moderate in severity, transient, and primarily limited to the day of dosing. There were three HLP003 treatment-related serious adverse events in the study. No new safety signals were identified.

 

About APPROACH and the PARADIGM Phase 3 Program

 

APPROACH is a Phase 3, multicenter, randomized, parallel-group, double blind, placebo-controlled trial of adjunctive treatment with HLP003 of adult participants with MDD. The Phase 3 study evaluated the efficacy and safety of HLP003 compared to placebo. The intent-to-treat population consisted of 222 participants with a DSM-5 confirmed diagnosis of MDD of moderate to severe degree as indicated by a MADRS total score of at least 24 at screening and baseline.

 

The baseline MADRS total scores of 32.7 for HLP003 and 33.8 for the placebo, reflected participants with moderate to severe depression. Participants continued taking their stable dose of antidepressant medication throughout the study.

 

APPROACH is the first of the three studies in the PARADIGM Phase 3 program, that also includes EMBRACE, the second pivotal study which is currently ongoing and the EXTEND study. The Company expects to report topline results from the EMBRACE trial in 4Q 2027. 2,3

 

EXTEND is the ongoing long-term extension study which will provide additional data on long-term safety, durability of effect, and the potential role of redosing. Participants from APPROACH and EMBRACE may roll into EXTEND.

 

Conference Call and Webcast

 

Helus Pharma will host a conference call and webcast today at 8:00 am ET to discuss results. To access the webcast, please visit the Events & Presentation page of Helus Pharma’s website. The archived webcast will be available on the Company’s website on the Events & Presentations page following the presentation.

 

 

 

 

About Helus Pharma

 

Helus Pharma is a clinical stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

 

Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the potential adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

 

The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

 

Notes

 

1.Pigott HE, et al., BMJ Open. 2023;13(7):e063095.

 

2.There is no assurance that this timeline will be met or that the program will advance clinical trials, at all. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development and recruitment of patients for participation in clinical trials are dependent on various factors and are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, the number, availability, location and accessibility of clinical trial sites, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company’s development efforts to date.

 

3.Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See “Forward-Looking Statements”.

 

Forward-Looking Statements

 

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements

 

 

 

in this news release include statements regarding the Company’s claim that the data demonstrate a therapeutic profile that has the potential to meaningfully improve outcomes for patients; expectations to report topline results from the EMBRACE trial in 4Q 2027; the potential regulatory approval and commercialization of HLP003; the APPROACH study’s potential to set higher expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant; expectations of the EXTEND study, including the roll-in enrollment of participants from EMBRACE and APPROACH; HLP003 as a potential adjunctive treatment for MDD; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions; and the timing of any of the foregoing.

 

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; the results of the Company’s clinical trials; the Company’s ability to pursue and obtain regulatory approval for its product candidates; the Company’s ability to enroll and retain participants in its clinical trials; the Company’s need for additional financing; the Company’s dependence on key personnel, including in connection with recent changes in management; the regulation of controlled substances; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and six months ended September 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca/ and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

 

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

 

Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

 

 

 

 

Contacts

 

Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
matthew.beck@astrpartners.com

 

Greg Cavers
Chief Financial Officer
Helus Pharma
1-866-292-4601 x715
irteam@helus.com – or – media@helus.com

 

Media Contact:
Charlotte Wray
RXMD
Chief Executive Officer
(212) 537-9495

Cwray@rxmedyn.com

 

 

 

Filing Exhibits & Attachments

1 document

Keep reading